Sagimet Biosciences (SGMT) announced it will host a virtual key opinion leader, KOL, event on Thursday, May 29, 2025. The event will feature Rohit Loomba, MD, MHSc, who will join company management to discuss the potential for developing a combination of denifanstat, a fat synthesis inhibitor, with a fat oxidizer, such as resmetirom, a thyroid hormone beta receptor agonist, to treat advanced metabolic dysfunction-associated steatohepatitis. The planned development program builds upon the successful results of the Phase 2b FASCINATE-2 clinical trial of denifanstat in MASH F2-F3 patients, particularly in more advanced F3 stage patients, as well as on preclinical data demonstrating the synergistic effect of a FASN inhibitor combined with resmetirom on important liver disease markers.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences, Inc.: A Promising Investment in the NASH Market with Strategic Growth Initiatives
- Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer
- Sagimet Biosciences Reports Q1 2025 Financial Results
- Sagimet Biosciences Reports Q1 Financial Results and Updates
- Sagimet Biosciences reports Q1 EPS (56c), consensus (69c)